Although its utility as a biomarker of kidney injury has not been explored as thoroughly as that of ACE2, NGAL, or KIM-1, NEP has recently become a major focus of clinical research due to the approval of sacubitril-valsartan, a first-in-class angiotensin receptor–NEP inhibitor, for chronic heart failure with reduced ejection fraction (McMurray et al., 2014). This evidence concerns the gene MME and congestive heart failure.